- Home
- PCB vs ZURA Comparison
PCB vs ZURA Comparison
Compare PCB & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCB | ZURA |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.1M | 455.4M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PCB | ZURA |
|---|---|---|
| Price | $27.45 | $4.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $25.50 | $13.00 |
| AVG Volume (30 Days) | 21.0K | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 48.28 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $2,899,000.00 | N/A |
| Revenue This Year | $13.73 | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $18.80 | ★ N/A |
| Revenue Growth | ★ 4.51 | N/A |
| 52 Week Low | $19.70 | $2.01 |
| 52 Week High | $30.84 | $7.25 |
Technical Indicators
Market Signals| Indicator | PCB | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 30.35 |
| Support Level | $27.21 | $4.36 |
| Resistance Level | $28.69 | $5.87 |
| Average True Range (ATR) | 0.46 | 0.36 |
| MACD | -0.00 | -0.16 |
| Stochastic Oscillator | 35.43 | 4.76 |
Price Performance
Historical ComparisonAbout PCB PCB Bancorp
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.